Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis

Saturday, March 13, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016 This is an essential source of information and analysis on the global coronary artery disease (CAD) market. The report identifies the key trends shaping
and driving the market and provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly the report provides valuable insight
into the pipeline products within the global CAD therapeutics sector. ( ) The Coronary Artery Disease Market is forecast to show Marginal Growth until 2016 The CAD market is currently very competitive and is expected to get more competitive in the future. The market is expected to witness a decline between 2011 and 2013 due to the patent expiries of a few blockbuster drugs used in the treatment of CAD. The major drug patent expiries expected in the coming years include Lipitor (atorvastatin) and Plavix in 2011 and Crestor (clopidogrel) in 2012. After 2014 the market is expected to grow due to the increase in the number of CAD patients and the entry of novel therapies into the market. The presently marketed products for the treatment of CAD have overall high efficacy and safety standards. The market also has two other modes of treatment which are coronary artery bypass grafting (CABG) and angioplasty. The CAD mortality rate is very high compared to other diseases due to coronary events associated with CAD including myocardial infarction (MI) angina and strokes. Therefore the prevention of such events still remains an untapped area of research and development for pharmaceutical companies to bring novel drugs into the market. It would therefore be sufficient for newer entrants to demonstrate a superior efficacy and safety profile in order to capture value in the market from the currently used branded and generic treatments. It analysis estimates that Darapladib Anacetrapib Aliskiren and SCH 530348 are likely to get market approval as these drugs are expected to bring higher efficacy and safety measures in the treatment of CAD. Some of these therapies are also likely to bring changes in the treatment approach by introducing much needed efficacy in the reduction of the progression of atherosclerosis in CAD patients. These novel therapies would remain market drivers in the future. Increases in the treatment seeking population prescription rates and the ageing global population are also considered to be important drivers for this market. It analysis shows that the market grew at a compound annual growth rate (CAGR) of 6.5% from $10.5 billion in 2001 to $17.4 billion in 2009. The market is predicted to grow at a marginal CAGR of 0.15% from 2009 and reach a total value of $17.6 billion by 2016. The marginal projected growth rate is primarily attributed to the patent expiries of some of the major marketed products like Lipitor and Crestor. The availability of new first-in-class therapies with better safety and efficacy profiles are expected to offset the negative impact of the patent expiry of major drugs and drive the growth of the CAD market in the future. Coronary Artery Disease Market is Set to Witness the Entry of Novel Class of Therapeutic Product It found the current competition in the CAD market to be strong as the market is mainly governed by branded and generic products that have comparable safety and efficacy profiles. This apart major revenues for this market are generated by statins antiplatelet and anticoagulants which are prescribed in addition to beta-blockers angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) to achieve superior treatment in patients. The antiplatelet and renin inhibitors (a new class of molecule) market is in itself set to witness a remarkable growth rate with the approval of newer drugs. The entry of these newer classes of drugs will undoubtedly accelerate the growth of the CAD market and also offset the negative impact of the patent expiry of major products. This would in turn start a race for a new class of pharmaceuticals with effective mechanisms of action. Merck & Co. Inc. is expected to lead sales in the CAD market with the introduction of Anacetrapib and SCH 530348 in the next few years. However other products such as Darapladib and Aliskiren are also likely to propel the growth of the market. To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Blog: Follow us on twitter:

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store